Imunon, Inc. – Common Stock (NASDAQ:IMNN) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.81) by 7.41 percent. This is a 3.33 percent increase over losses of $(0.90) per share from the same period last year.
RAPT Therapeutics Stock Soars As Atopic Dermatitis Candidate Shows Promising Action In Early-Stage Study
RAPT Therapeutics Inc (NASDAQ:RAPT) has announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis…